Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATR | Q13535 | 18/20 | 0.67 |
| ▸ | ATRIP | Q8WXE1 | 8/20 | 0.67 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.67 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.67 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.67 |
| ▸ | PIK3CA | P42336 | 4/20 | 0.64 |
| ▸ | MTOR | P42345 | 4/20 | 0.64 |
| ▸ | PRKDC | P78527 | 2/20 | 0.64 |
| ▸ | TAF1 | P21675 | 1/20 | 0.64 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.64 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.64 |
| ▸ | ATM | Q13315 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3093025 | 0.86 | PIK3CA (0.70) | ATRATRIPCHEK1PDCD1CD274 | |
| SCHEMBL3093087 | 0.85 | PIK3CA (0.80) | ATRATRIPCHEK1PDCD1CD274 | |
| SCHEMBL3090335 | 0.80 | ATR (0.77) | ATRATRIPCHEK1PDCD1CD274 | |
| SCHEMBL3081948 | 0.80 | MTOR (0.61) | ATRATRIPCHEK1PDCD1CD274 | |
| SCHEMBL7907534 | 0.80 | ATR (0.80) | ATRATRIPCHEK1PDCD1CD274 | |
| SCHEMBL20651808 | 0.80 | ATR (1.00) | ATRATRIPCHEK1PDCD1CD274 | |
| SCHEMBL21263052 | 0.79 | ATR (0.75) | ATRATRIPCHEK1PDCD1CD274 | |
| SCHEMBL21263177 | 0.79 | ATR (0.75) | ATRATRIPCHEK1PDCD1CD274 | |
| SCHEMBL3594878 | 0.79 | PIK3CA (0.61) | ATRATRIPCHEK1PDCD1CD274 | |
| SCHEMBL3081989 | 0.79 | PIK3CA (0.60) | ATRATRIPCHEK1PDCD1CD274 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100227858-A1 | TRISUBSTITUTED PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF PROLIFERATIVE DISEASES | ASTRAZENECA AB (SE) | 2010-09-09 | — | — | US | claimed |
| EP-2176256-A2 | TRISUBSTITUTED PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF PROLIFERATIVE DISEASES | AstraZeneca AB (SE) | 2010-04-21 | — | — | EP | claimed |
| WO-2009007751-A2 | TRISUBSTITUTED PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF PROLIFERATIVE DISEASES | ASTRAZENECA AB (SE) | 2009-01-15 | — | — | WO | claimed |
| US-20100227858-A1 | TRISUBSTITUTED PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF PROLIFERATIVE DISEASES | ASTRAZENECA AB (SE) | 2010-09-09 | — | — | US | disclosed |
| US-20100227858-A1 | TRISUBSTITUTED PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF PROLIFERATIVE DISEASES | ASTRAZENECA AB (SE) | 2010-09-09 | — | — | US | disclosed |
| US-20100227858-A1 | TRISUBSTITUTED PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF PROLIFERATIVE DISEASES | ASTRAZENECA AB (SE) | 2010-09-09 | — | — | US | disclosed |
| EP-2176256-A2 | TRISUBSTITUTED PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF PROLIFERATIVE DISEASES | AstraZeneca AB (SE) | 2010-04-21 | — | — | EP | disclosed |
| WO-2009007751-A2 | TRISUBSTITUTED PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF PROLIFERATIVE DISEASES | ASTRAZENECA AB (SE) | 2009-01-15 | — | — | WO | disclosed |
| WO-2009007751-A2 | TRISUBSTITUTED PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF PROLIFERATIVE DISEASES | ASTRAZENECA AB (SE) | 2009-01-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100227858-A1 | TRISUBSTITUTED PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF PROLIFERATIVE DISEASES | MTOR, PIK3CA, PIK3CD | ATR 706/4885ATRIP 2906/4885CHEK1 135/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.